Unknown OBSERVATIONAL NCT06287320

The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer

The Peripheral Blood Lymphocyte Subsets as Predicative Biomarkers Reflecting the Efficacy and Toxicity in Patients With Locally Advanced Non-small Cell Lung Cancer Received Chemoradiotherapy With or Without Immunotherapy

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions Locally Advanced Non-small Cell Lung Cancer

Interventions Immunotherapy concurrent or sequential chemoradiotherapy

Updated 4 times since 2024 Last updated: Feb 23, 2024 Started: Mar 1, 2024 Primary completion: Dec 31, 2025 Completion: Feb 28, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Locally Advanced Non-small Cell Lung Cancer, this trial is ongoing. The trial is conducted by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and has accumulated 4 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Mar 2026 — Present [monthly]

Unknown

Status: Recruiting → Unknown
Sep 2024 — Mar 2026 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Apr 2024 — Jul 2024 [monthly]

Recruiting

First recorded

Mar 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Data source: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China